0001181431-12-041391.txt : 20120719
0001181431-12-041391.hdr.sgml : 20120719
20120719200703
ACCESSION NUMBER: 0001181431-12-041391
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120717
FILED AS OF DATE: 20120719
DATE AS OF CHANGE: 20120719
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NARACHI MICHAEL
CENTRAL INDEX KEY: 0001380022
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33415
FILM NUMBER: 12970791
MAIL ADDRESS:
STREET 1: C/O ADVANCED MAGNETICS, INC.
STREET 2: 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Orexigen Therapeutics, Inc.
CENTRAL INDEX KEY: 0001382911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 651178822
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3344 N. TORREY PINES CT.
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 875-8600
MAIL ADDRESS:
STREET 1: 3344 N. TORREY PINES CT.
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
4
1
rrd351245.xml
FORM 4 - NARACHI
X0306
4
2012-07-17
0
0001382911
Orexigen Therapeutics, Inc.
OREX
0001380022
NARACHI MICHAEL
C/O OREXIGEN THERAPEUTICS, INC.
3344 N. TORREY PINES COURT, SUITE 200
LA JOLLA
CA
92037
1
1
0
0
President and CEO
Common Stock
2012-07-17
4
M
0
124238
1.66
A
124238
D
Common Stock
2012-07-17
4
S
0
124238
7.66
D
0
D
Common Stock
2012-07-17
4
M
0
25762
1.70
A
25762
D
Common Stock
2012-07-17
4
S
0
25762
7.66
D
0
D
Stock Option (right to buy)
1.66
2012-07-17
4
M
0
124238
D
2021-07-24
Common Stock
124238
1761562
D
Stock Option (right to buy)
1.70
2012-07-17
4
M
0
25762
D
2021-06-09
Common Stock
25762
1774238
D
The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) (which option is referred to in this Form 4 as the "Replacement Grant") shall vest on the same day of each one-month period of the reporting person's service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
Not applicable.
1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest and become exercisable on the same day of each month after June 10, 2011, so that all of the shares of the stock subject to the option shall be vested in full on June 10, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
/s/ Heather D. Turner, Attorney-in-fact
2012-07-19